United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

30 Nov 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IPXL.OQ


Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics... (more)


Beta: 1.32
Market Cap(Mil.): $1,052.78
Shares Outstanding(Mil.): 73.88
Dividend: --
Yield (%): --


  IPXL.OQ Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -2.54 -- --
ROI: -10.21 15.56 14.95
ROE: -18.73 16.69 16.29

BRIEF-Impax appoints J. Kevin Buchi to board

* Impax announces appointment of J. Kevin Buchi to board of directors Source text for Eikon: Further company coverage:

Nov 28 2016

BRIEF-Impax Q3 adjusted EPS $0.37

* Sees total company revenues of approximately $840 million to $855 million (previously $900 million to $940 million)

Nov 09 2016

Endo contract lawsuit against Impax over Opana gets green light

Endo Pharmaceuticals Inc, maker of the opioid painkiller Opana ER, can proceed with a lawsuit accusing Impax Laboratories Inc of breaching a settlement agreement that allowed the latter to sell a generic version of the drug, a federal judge has ruled.

Oct 27 2016

BRIEF-Impax Laboratories announces launch of generic version of Metadate CD

* Announced launch of a generic version of Metadate CD Source text for Eikon: Further company coverage:

Sep 22 2016

BRIEF-Sqi Diagnostics sells Sqidlite System to Global Pharmaceutical Customer

* SQI sells Sqidlite System to Global Pharmaceutical customer Source text for Eikon: Further company coverage:

Aug 30 2016

BRIEF-Impax Laboratories issues nationwide recall for one lot of ODT

* Impax laboratories Inc issues voluntary, nationwide recall for one lot of Lamotrigine Orally Disintegrating Tablet 200 mg due to the potential for 100 mg blister cards being packaged in 200 mg containers

Aug 26 2016

Judge trims reverse payment claims against Endo, Impax over Opana

A federal judge has trimmed state law claims brought by health plans in a class action lawsuit claiming that Endo Pharmaceuticals Inc paid a rival drugmaker to delay the launch of a generic version of Endo's painkiller Opana ER, forcing the health plans to pay higher prices by preventing competition.

Aug 15 2016

BRIEF-Impax Laboratories reports Q2 GAAP loss per share $0.04

* Q2 earnings per share view $0.32 -- Thomson Reuters I/B/E/S

Aug 09 2016

UPDATE 2-Teva, Allergan win U.S. antitrust approval for generics deal

WASHINGTON, July 27 Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

Jul 27 2016

Impax buys generic drugs from Teva, Allergan for $586 million

Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.

Jun 21 2016

Earnings vs. Estimates